CCCC insider trading
NasdaqGS HealthcareC4 Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Company website: www.c4therapeutics.com
CCCC insider activity at a glance
FilingIQ tracks 327 insider transactions for CCCC in filings since Oct 6, 2020. The most recent transaction is dated Oct 1, 2026.
Across the full history, 5 open-market purchases
and 54 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CCCC insider trades is 55.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CCCC Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CCCC?
- FilingIQ tracks 327 Form 4 insider transactions for CCCC (C4 Therapeutics, Inc.), covering filings from Oct 6, 2020 onwards. 6 of those are dated within the last 90 days.
- Are CCCC insiders net buyers or net sellers?
- Across the full Form 4 history for CCCC, 5 transactions (2%) were open-market purchases and 54 (17%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CCCC insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is CCCC in?
- C4 Therapeutics, Inc. (CCCC) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $185.11M.
Methodology & sources
Every CCCC insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.